Key result
Modulating autophagy with pharmacological and natural agents shows therapeutic potential against doxorubicin-induced cardiomyopathy.
Why the study?
The precise mechanism by which doxorubicin modifies autophagy remains unclear, as its role in heart tissue is controversial, ranging from cytoprotective to cytotoxic.
Does autophagy modulation mitigate cardiac damage in doxorubicin-induced cardiomyopathy?
Does autophagy modulation mitigate cardiac damage in doxorubicin-induced cardiomyopathy?
This review highlights the mechanistic role of autophagy in doxorubicin-induced cardiomyopathy and explores therapeutic interventions targeting autophagy for cardioprotection.
No immediate practice change in doxorubicin cardiomyopathy; leaves open clinical translation of autophagy modulation.
Autophagy has been extensively studied in a variety of pathologies, including neurological disorders, cancers, muscle diseases, aging, and cardiovascular diseases. Doxorubicin (Dox) is a potent anticancer drug widely used to treat various cancers. Despite its therapeutic benefits, it has cardiotoxic side effects, interfering with its clinical application. Dox-induced cardiomyopathy (DIC) is one of the most prominent and lethal side effects associated with the use of Dox. Numerous investigations have revealed that Dox administration impacts autophagy; however, the precise mechanism by which Dox modifies this process remains unclear, as the role of autophagy in heart tissue is controversial, ranging from being cytoprotective to cytotoxic. Various therapeutic interventions, including pharmacological drugs and natural products, have been reported to influence the autophagic flux in DIC. In this review, we explore the therapeutic potential of autophagy modulation in DIC, focusing on how various pharmacological drugs and natural products influence autophagy to mitigate cardiac damage. This review uniquely emphasizes the mechanistic role of autophagy in DIC and provides a comprehensive analysis of therapeutic interventions targeting autophagy as a strategy for cardioprotection.
No takes yet. Share an insight, caveat, or question.
Badr et al. (2026) conducted a review in Doxorubicin-induced cardiomyopathy. Autophagy modulation (pharmacological drugs and natural products) was evaluated. Modulating autophagy with various pharmacological drugs and natural products offers therapeutic potential to mitigate cardiac damage in Doxorubicin-induced cardiomyopathy.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: